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ABSTRACT
Martin, Jamee Covington. M.S. The University of Memphis. 12/2011. Chemotherapy
Induced Mucositis: A Novel Porcine Model. Major Professor: Dr. Randal K. Buddington

Chemotherapy-induce mucositis (CIM) is a dose-limiting side effect of cancer
therapy with concurrent nausea, vomiting, diarrhea, lethargy, and decreased food
consumption. Of the pediatric population approximately 40% of patients receiving
standard dose and 100% of patients receiving high dose chemotherapy are afflicted.
Although scientific advancements have improved pediatric cancer survival rates,
occurrence of mucositis decreases quality of life, increases treatment interruptions or
even delays therapy, and often reduces the dose. Currently, there are no relevant animal
models studying the entire gastrointestinal tract (GIT). Based on these findings, we
decided to develop a novel porcine model for CIM. Examination of the entire GIT with
coinciding clinical symptom, lead to the findings of CIM with the administration of
single dose Doxorubicin, HCL (75mg/m2). A novel porcine CIM model will permit for an
improved understanding of the disease process with regard to chemotherapy dosing and
potential future intervention therapy.
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CHAPTER I
INTRODUCTION
Innovative cancer therapies utilize prognostic models for determining the
anatomical characteristics of various cancers for proper diagnosis. Cancer is
characterized by the growth and spread of abnormal cells through the impact of external
and internal risk factors. The type, location, severity of growth, metastasis, and size of the
cancer allows for differentiation and therefore choice of therapy 1.
The frontline therapy for the treatment of cancer is the administration of
chemotherapeutic agents. Anthracyclines, a class of chemotherapeutic agents, are antitumor antibiotics that impede DNA replication enzymes. Due to the mechanism of action
of anthracyclines, there is a profound influence on normal cells that divide rapidly, such
as the stem cells in the mucosa of the gastrointestinal tract (GI).
Post-chemotherapy administration the GI mucosa is damaged, resulting in a
painful adverse effect known as chemotherapy induced mucositis (CIM) that is
characterized by inflammation of the mucosal lining within the alimentary tract. Mucosal
damage associated with CIM is the most common dose limiting side effect of
chemotherapy. CIM produces swollen and painful ulcerations within 5 to 14 days postadministration of the chemotherapeutic agent. The pain induced by CIM can diminish a
patient’s ability to eat, talk, drink or swallow thus resulting in delayed and often alters
dosing of chemotherapeutic treatments and compromises appropriate nutrition therapy.
The signs and symptoms of CIM begin with the onset of vomiting, diarrhea, a decrease in
caloric intake and weight loss 2.
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Investigational animal models aid in the development of disease interventions.
Research on CIM is dominated by investigations conducted on mice, rats or in vitro
processes. The present research aims to develop a novel porcine animal model for the
induction of chemotherapy-induced mucositis (CIM). The objectives of this study are to
determine the timeline and dosing regimen of chemotherapy to induce alimentary tract
mucositis. Although prior investigations of CIM have been invaluable for the
advancements made in physiological concepts, a porcine model would be more relevant
to human CIM and would yield translational data 3-6. The porcine model shares more
similarities with humans than rodent species with regard to the anatomical, physiological,
immunological, and metabolic characteristics 7-9.
Combining an appropriate animal, the pig, with a clinically relevant
chemotherapeutic agent, in this case Doxorubicin (DOXO), was the basis for the
development of a novel animal model of CIM 10. A relevant animal model can be utilized
for the advancement and evaluation of CIM interventions. At this time the interventions
available for the alleviation of CIM are marginally effective and include oral numbing
medications, intravenous pain medications, relaxation techniques, and cessation of
treatment. The availability of a relevant animal model is imperative to the future
development of interventions for treatment and prevention of CIM.
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REVIEW OF LITERATURE
Malignant neoplasms are locally invasive with destructive growth and possible
metastasis. Neoplasms are tissues set apart from adjacent normal tissues by abnormally
rapid proliferation with continued growth post irregular stimulation. Metastasis involves
cancer cells and the disease process disseminating from the primary tumor site to
secondary regions of the body via the lymphatic system, blood vessels, or by direct
extension via cavities or other spaces. Essentially, cancer involves the progressive
accumulation of genetic changes that facilitate irregular and rapid proliferation of cells
with the potential to spread to surrounding tissue via diverse metabolic pathways 11.
Pediatric Cancers
In 2010, approximately 10,700 new cases or one percent of all cancer patients
were represented by children under the age of 20 years old 1,12,13. The most prevalent
pediatric cancers include Hodgkin and non-Hodgkin lymphoma, Acute Lymphoblastic
Leukemia (ALL), Acute Myeloid Leukemia (AML), brain tumors, and Wilms’ tumor, a
childhood solid tumor of the kidneys 1,12-16.
Lymphomas cause swollen lymph nodes and have the potential to metastasize to
the bone marrow and other organs. Leukemias are a progressive proliferation of abnormal
leukocytes, white blood cells (WBC), typically found in hemopoitetic tissues and in the
blood. Wilms’ tumor is diagnosed by a lump or swelling of the abdomen. Combined,
these cancers represent approximately 66% of all childhood cancers 1,11.
Cancer Progression
When cancer presents itself, early detection is crucial to the effectiveness of
cancer interventions 17. Anatomical characteristics in addition to prognostic models
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determining size, location, and severity allow for early detection to ensure proper
diagnosis and therefore choice of therapy 1. A multitude of interventions or therapies are
currently available in various therapeutic regimens. Interventions range from surgical
resection to chemotherapy and radiotherapy or combination therapy to create a
synergistic effect.
Anthracycline Agents for Cancer Chemotherapy
One class of chemotherapeutic agents known as anthracyclines, plays a vital role
in the treatment of many pediatric cancers 15. In the 1960s cultures of Streptomyces
peucetius were discovered to have cytotoxic antineoplastic properties 18, leading to the
development of the anthracycline drugs now used in pediatric oncology. More than 50%
of pediatric cancer survivors have received anthracycline chemotherapeutic agents as a
part of their cancer treatment regimen. Anthracycline agents are considered to be a key
reason why the 5-year survivor rate has increased from approximately 30% in the 1960s
to approximately 70-80% today 15.
Doxorubicin (Adriamycin)
Doxorubicin (DOXO hereafter) is marketed for intravenous use only. The most
commonly used dosage of DOXO for pediatric patients is 40 to 60 mg/m2 and is
administered as a single intravenous injection every 21 to 28 days. Some modifications
are necessary depending on the current health status of the individual patient 18.
Variations of co-treatment options differ depending on the type and extent of cancer.
The anticancer properties of DOXO are attributed to inhibition of topoisomerase
II, which is essential for DNA replication and repair by resolving DNA under and overwinding, knots and tangle complications that exist within genetic material 15,19. DOXO
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interferes with the performance of topoisomerase II through intercalation, which is an
insertion of DOXO between the DNA strands. This effectively inhibits proliferation of
rapidly growing cancer cells by blocking DNA replication 11,15. The result of DOXO
administration is a blockage of the cell cycle at the G2/M phase. Basically, by blocking
DNA replication and the cell cycle (mitosis), DOXO inhibits further replication of cancer
cells. Moreover, DNA binding to the anthracycline instead of the topoisomerase leads to
the apoptotic pathway or programmed cell death (PCD) 20. This mechanism is the body’s
mechanisms of eliminating cells that are not capable of reproducing. In essence the cell
dies due to the inhibition of cellular replication, with rapidly proliferating cancer cells
preferentially affected.
Gastrointestinal Tract Susceptibility to DOXO
Unfortunately, cancer cells are not the only rapidly proliferating cells within the
body. The gastrointestinal tract (GIT) epithelium, from the mouth to the anus, is a highly
proliferative system. Cell turnover rates within the GIT are approximately 24 to 48 hours.
Because of the limited lifespan as well as the limited selectivity of the anthracycline, the
GIT becomes susceptible to the mechanism of action of the anthracycline antibiotic,
DOXO 21. In short, DOXO affects proliferation of GIT cells as well as cancer cells. In
addition to the GIT there are other tissues in which DOXO produces side effects but these
effects will not be discussed in detail. Due to the impact of DOXO on tissues dependent
on highly proliferative cells, side effects include mucositis, nausea, vomiting associated
with the GIT, alopecia (hair loss), and anemia 14.
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Progression of Mucositis Phases and the Significance of Cytokines
Mucositis is the focus of this research and literally means inflammation of the
mucosal lining of the digestive system. Mucositis develops within 5 to 10 days after onset
of treatment. It is described as an adverse reaction of the gastrointestinal section in the
prescribing information of the medication 18. All regions of the alimentary tract from
mouth to anus are susceptible to mucosal damage caused by DOXO and other
chemotherapeutic agents. The theory behind the pathophysiology of mucositis is
activation of nuclear factor KB (NF-KB). NF-KB promotes the upregulation of key proinflammatory cytokines, such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β)
and interleukin-6 (IL-6). These pro-inflammatory cytokines are considered to play an
important role in the five phases of mucositis development and progression. These
include initiation, upregulation and message generation, signal amplification, ulcerative,
and healing phases 22,23. The initiation phase occurs immediately after exposure to the
cytotoxic agent and involves direct damage to the mucosal tissue components due to the
production of reactive oxygen species (ROS). ROS are a by-product of the reactions
involved with chemotherapy metabolism 24. The upregulation and message generation
phase incorporates the activation of the transcription factor NF-KB in response to the
chemotherapy administration. Once activated, NF-KB signals up to 200 genes that trigger
clonogenic cell death, apoptosis, and mucosa tissue damage. Additionally, the proinflammatory cytokines, TNF, IL-B, and IL-6, are produced in response to the activation
of NF-KB 23. The signal amplification phase involves pro-inflammatory cytokines
triggering additional NF-KB activation and thus more pro-inflammatory cytokines are
produced in response to the second NF-KB activation. The ulcerative phase occurs as
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soon as there is a breach in the epithelium, which can be accompanied by bacterial
colonization. It is only at this stage when tissue damage produced by mucositis is
clinically evident. Finally, the healing phase is induced after cessation of the
chemotherapy treatment. Clinical evidence indicates as mucositis resolves, reepithelialization takes place 23.
DOXO and Mucositis: Side Effect and Dose Limitation
The degree of mucositis, including the incidence and severity, are related to the
amount and type of chemotherapy administered. Even conventional dosing schedules can
induce potentially serious complications, such as severe local discomfort, pain, and
diminished nutrition status, dehydration, debilitating oral pain as a result of ulcerations,
abdominal bloating, vomiting, and diarrhea. These side effects can delay subsequent
chemotherapy and lead to dose reductions if there is no resolution of the mucositis 23.
Inevitably, this reduces chemotherapy efficacy and can decrease in the survival rate of the
cancer patient population due to the provision of altered treatment below therapeutic
standards 25. Therefore, mucositis is classified as one of the major dose limiting factors of
chemotherapy. If mucositis were to be alleviated or even prevented from occurring in
patients undergoing chemotherapy, the degree of suffering would be lessened, and dosage
could be increased 25.
Mucositis Treatment Options
Current clinical treatments for patients diagnosed with mucositis are limited to
oral analgesics and intravenous pain medications. Growth factors, cytokines, receptor
agonists/antagonists, and anti-inflammatory agents are being explored as treatment
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options 26. A limiting factor in the development and evaluation of interventions for
mucositis is the availability of relevant animal models.
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CHAPTER II
MATERIALS AND METHODS
Pigs and their Care
The University of Memphis Institutional Animal Care and Use Committee had
approved all aspects of the research involving animals (UM IACUC protocol #0672). A
total of 12 weaned farm pigs approximately 28 days old ± 4 days were obtained from a
commercial specific pathogen free supplier. The pigs were housed in Polydome Litter
Saver Pig Nurseries divided into two sections with final dimensions of 61cm by 76cm,
with environmental enrichment provided, and located in a room maintained at 22 C (+ 1°
C). The pigs were housed individually and fed Prime Quality Pig Starter (Cargill
Incorporated Minneapolis, MN) three times each day at 150 g per feeding. The pigs were
allowed access to the food for 15 minutes after which the remaining food was weighed
for estimating daily consumption. The intensity of feeding was also recorded as a
subjective indicator. Water was continuously available. The pigs were weighed and had
daily frequent human interactions to facilitate chemotherapy administration and handling
27,28

.

Surgical Catheterization
Catheters (3.5 French Umbilical Artery Catheters) were surgically placed in the
right carotid artery and exteriorized on the dorsal surface at the base of the neck for
collection of blood and for administration of the chemotherapeutic agent, Doxorubicin,
HCL (DOXO; Bedford Laboratories, Bedford, OH). The surgery was performed 3 days
after the pigs were obtained, allowing the pigs to acclimate to the new environment and
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feeding regimen. The pigs were fasted overnight before the surgery. The pigs were
sedated with Telazole (10 mg/kg), anesthesia was maintained using Isoflurane (2% with
oxygen), and a sterile surgical field was prepared. Carprofen (4 mg/kg) was used post
surgery for analgesia and Baytril (5-10 mg/kg) was administered prophylactially to
prevent infection. The catheters were flushed 2-3 times daily with heparinized saline (100
units/ml).
Administration of Doxorubicin
The pigs were allowed to recover for a minimum of two days after surgery or
until pre-surgery feeding intensity was regained before administration of DOXO. The
doses (Table 1) were calculated for each pig as the appropriate Human Equivalent Dose
(HED)/Animal Dose (AD) 29-30. A preliminary pig was administered 6.25 mg/kg (125
mg/m2; n=1). This dose exceeds by roughly 2-fold the maximum dose that would be
provided to a child. The intention was to determine if DOXO would induce GI
dysfunctions as in humans. The remaining pigs were administered DOXO at 5 mg/kg
(100 mg/m2; n=4) and the clinically relevant dose of 3.75 mg/kg (75 mg/m2; n=4). The
dosages were provided via the catheter over a 30 min period by administering 1/6th of the
dosage every 5 minutes per pig. Control pigs (n=3) received the same volume of saline
using the same dosing regimen. The feeding regimen was maintained after
administration of DOXO.
An additional two of the pigs dosed with 75 mg/m2 DOXO were provided bovine
colostrum at 5 ml/kg body weight 3x/d beginning the day before and continuing after
administering the dose of DOXO. This was to evaluate if colostrum would alleviate the
adverse impact of DOXO on gastrointestinal structure and functions.
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Table 1. Doxorubicin dosages used to induce mucositis in weaned pigs.
Group

Human Equivalent Dose

Animal Dose

(HED)

(AD)

n

1

125mg/m2

6.25mg/kg

1

2

100 mg/m2

5mg/kg

4

3

75 mg/m2

3.75mg/kg

4

4

0; Lactated Ringers

2 ml/kg

3

Data Collection
Food consumption (intensity of feeding and amount eaten) was recorded daily
before and after administration of DOXO. After DOXO was administered each pig was
observed a minimum of 3 times daily and general health status, vomiting frequency, stool
consistency (assessed according to Table 2) and body weight were reported 35.

Table 2. Diarrhea Assessment Chart
Stool Score

	
  

Stool Grade/ Consistency

Description

0

Normal Stool

Normal or Absent Stool

1

Slight Diarrhea

Slightly Wet and Soft Stool

2

Moderate Diarrhea

3

Severe Diarrhea

Wet and Unformed Stool
Moderate Coat Staining Around the Anus
Watery Stool
Severe Coat Staining Around the Anus

11

Cytokines
Blood samples were collected in EDTA tubes immediately prior to the
administration of DOXO, every morning thereafter, and immediately prior to euthanasia.
Blood samples were centrifuged and aliquots of the plasma were frozen (-70° C) until
used to measure concentrations of inflammatory (IL-6, TNF-α) and anti-inflammatory
(IL-10) cytokines by enzyme-linked immunosorbent assays (ELISA; R&D Systems,
Minneapolis, MN) following the manufacturer's instructions.
Necropsy and Tissue Collection
After euthanasia (Beuthanasia, Schering-Plough Animal Health Corp., Union, NJ,
1ml/kg; IV) the mouth was examined for lesions. The entire gastrointestinal tract was
exposed and externally visible lesions were recorded. A 1-2 cm segment of esophagus
immediately distal to the pharynx was removed and placed in neutral buffered formalin.
The stomach was opened, the interior was observed and a 1-2 cm2 full thickness patch
from the greater curvature was fixed in formalin. The small intestine was removed, the
associated mesenteries cut, and length measured from the pyloric sphincter to the
ileocolonic junction. Intact segments of 15-20 cm were removed from the proximal, mid
and distal thirds of the small intestine (Figure 1). From each of these regions a 1-2 cm
segment was fixed in formalin, another 5-7 cm was flash frozen in liquid nitrogen and
stored at -70° C, and the remainder of the segment was placed in chilled (2-4° C)
mammalian Ringers and transferred to the lab for in vitro studies (data not presented).
Segments of 1-2 cm were removed from the proximal, mid, and distal colon and fixed in
formalin.
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Histology
The tissues were processed by Integrated Microscopy Center at the University of
Memphis. Briefly, the full thickness, formalin fixed tissues were dehydrated, embedded
in paraffin and 5 µm sections were stained with Lillie–Mayer’s haematoxylin and
counterstained with eosin. Histopathology observations were performed on a light
microscope with an optical micrometer.
The overall severity of mucositis in the jejunum and proximal colon was scored
based on a semi-quantitative histological assessment of intestinal damage 31. Each region
was assessed and given a summative value based on the following scores, 0 (normal) to 3
(maximal damage). The maximum possible score, 21, was based on the following
inclusion criteria, villus fusion and stunting (atrophy), disruption of brush border and
surface enterocytes, reduction in goblet cell number, crypt loss/architectural disruption or
distortion of crypt cells, infiltration of polymorphonuclear cells and lymphocytes, in
addition to thickening and edema of submucosal and mucularis external layers.
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Distal

CHAPTER III
RESULTS
Food Consumption, Body Weight Gain, and General Health
Control pigs continued to eat the ration aggressively, gained body weight,
responded to enrichment and human interactions, and remained healthy based on stool
scores and lack of vomiting or any evidence of GI dysfunctions (Figures 2-5; Tables 3-6).
Administration of DOXO at all doses elicited rapids declines in food consumption
and weight loss (Figures 2-3; Tables 3-4). Within 24 h after DOXO administration the
pigs lost interest in enrichment and human interactions and became lethargic. Vomiting
was first seen 24 h after the dosage and became severe on day 3 (Figure 4; Table 5). By
this time food consumption fell below 20% of pre-administration intake. Vomiting
declined thereafter and was not seen the day of necropsy. Stool consistency declined
rapidly after DOXO administration, and particularly after day 2. Profuse watery diarrhea
was evident until necropsy (Figure 5; Table 6). All pigs receiving DOXO exhibited signs
of wasting at day 4-5, based on continued weight loss and the prominence of bony
processes associated with the pelvis, scapula, and spine, with reduced abdominal adipose
tissue and muscle tone. At the time of necropsy, pigs dosed with DOXO had lost 5-20%
of body mass compared with the start of chemotherapy 27.
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Figure 2. Comparison of food consumption between Control and Doxorubicin group 1
day before and after administration of 75mg/m2 until necropsy. Values are expressed as
percentages of pre-administration values.

Table 3. Comparison of food consumption between Control and Doxorubicin group 1 day
before and after administration of 75mg/m2 until necropsy. Values are expressed as
percentages of pre-administration values.
Daily Food Consumption

	
  

Average Daily Intake

Doxorubicin

Control

Day -1

93.20%

51.77%

Day 0

65.5%

68.97%

Day 1

58.4%

60.23%

Day 2

45.7%

67.57%

Day 3

19%

59.87%

Day 4

7.37%

82%

Day 5

10%

92.7%

16

Figure 3. Comparison of body weight change between Control and Doxorubicin group 1
day before and after administration of 75mg/m2 until necropsy. Values are expressed as
percentages of pre-administration values.

Table 4. Comparison of body weight change between Control and Doxorubicin group 1
day before and after administration of 75mg/m2 until necropsy. Values are expressed as
percentages of pre-administration values.
Weight Change
Average Daily Intake

Doxorubicin

Control

Day -1

+10.9%

+7.53%

Day 0

+6.66%

+7.31%

-17.16%

+16.89%

Day 1
Day 2
Day 3
Day 4
Day 5
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Figure 4. Changes in vomiting between Control and Doxorubicin group 1 day before and
after administration of 75 mg/m2 of Doxorubicin until necropsy. Values are expressed as
percentages of pre-administration values.

Table 5. Changes in vomiting between Control and Doxorubicin group 1 day before and
after administration of 75 mg/m2 of Doxorubicin until necropsy. Values are expressed as
percentages of pre-administration values.
Vomiting

	
  

Average Daily Intake

Doxorubicin

Control

Day -1

0%

0.0%

Day 0

0%

0.0%

Day 1

0%

0.0%

Day 2

5.6%

0.0%

Day 3

50.0%

0.0%

Day 4

22.2%

0.0%

Day 5

0.0%

0.0%

18

Figure 5. Incidence of diarrhea between Control and Doxorubicin group 1 day before and
after administration of 75 mg/m2 of Doxorubicin until necropsy. Values are expressed as
percentages of pre-administration values.

Table 6. Incidence of diarrhea between Control and Doxorubicin group 1 day before and
after administration of 75 mg/m2 of Doxorubicin until necropsy. Values are expressed as
percentages of pre-administration values.
Diarrhea

	
  

Average Daily Intake

Doxorubicin

Control

Day -1

0.0%

0%

Day 0

3.7%

0%

Day 1

3.7%

0%

Day 2

11.1%

0.0%

Day 3

74.1%

0.0%

Day 4

100.0%

0.0%

Day 5

100.0%

0.0%

19

Cytokine Data

Figure 6. TNF-α cytokine concentrations. Values are expressed in pg/ml. Day 0 indicates
the initial sample prior to chemotherapy with all days leading to necropsy on day 5.

Figure 7. IL-6 concentrations. Values are expressed in pg/ml. Day 0 indicates the initial
sample prior to chemotherapy with all days leading to necropsy on day 5.
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Figure 8. IL-10 concentrations. Values are expressed in pg/ml. Day 0 indicates the initial
sample prior to chemotherapy with all days leading to necropsy on day 5.
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Histopathology
The jejunum and proximal colon of pigs receiving DOXO had disrupted
morphology and structural integrity (Figure 9). This was evident at all doses, including
(75mg/m2). Microscopic examination of control pigs (Figure 9) did not reveal evidence
of epithelial hyperplasia, structural or cellular alterations, or significant histological
changes.
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Figure 9. Control jejunum (A) and proximal colon (C). Doxorubicin administration
(75mg/m2): Severe jejunal villous atrophy and blunting (B) and diminished proximal
colon crypt depth or goblet cell presentation (D).
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CHAPTER IV
DISCUSSION
Chemotherapy alone or in conjunction with surgery or radiation remains the
cornerstone of cancer therapy and has contributed to the rise in pediatric cancer survival
rates 32. Anthracyclines (DOXO) are a recognized class of chemotherapy known to have
contributed to the steady improvements in prevailing over pediatric cancers 33, 34.
However, future research is required to develop safe and effective interventions for the
debilitating and potentially dose limiting factors associated with the side effects of
chemotherapies.
The dose limiting factor, mucositis, afflicts approximately 40% of patients
receiving standard dose and 100% of patients receiving high dose chemotherapy 35,36.
Agents such as DOXO, are known to amplify these mucotoxic findings 37,38. Although
scientific advancements have improved pediatric cancer survival rates, occurrence of
mucositis decreases quality of life, increases treatment interruptions or even delays
therapy, and often reduces the dose 23,32,39.
General Health and Clinical Symptoms
Mucositis in response to chemotherapy is defined by inflammatory lesions of the
mucosal lining of the oral and/or gastrointestinal tract as a result of standard or high-dose
cancer therapy 40,41. This study demonstrated mucositis develops similarly in weaned pigs
after administration of DOXO at 75 mg/m2, 100 mg/m2, and 125 mg/m2. At 75 mg/m2,
which is a clinically relevant dose, mucositis characteristics were comparable to those
described for pediatric cancer patients receiving chemotherapy. Although the pigs did not
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vocalize discomfort, the symptoms of mucositis were evident based on the declines in
food consumption and weight gain, the increased frequency of vomiting, and diarrhea,
and lethargic behavior. These responses are consistent with literature reports pertaining
to pediatric oncology and chemotherapy.
A multitude of factors influence chemotherapy-induced nausea and vomiting
(CINV). Pediatric patients are especially at higher risk for emesis solely based on age.
There are varying theories indicating chemotherapy’s interference/influence on the vagus
nerve, which activates the dorsal vagal complex 42. This is considered to be the primary
mechanism by which most chemotherapeutic agents initiate acute emesis. Emetogenic
levels of intravenously administered antineoplastic agents have been classified into four
divisions (high, moderate, low, and minimal) and these have been the standard for
defining emetogenicity. DOXO was categorized as moderate, with 31% to 90% of
patients anticipated to develop vomiting 42-44.
After onset of CINV, food consumption declines and is followed by cancer
cachexia, which affects almost two thirds of cancer patients and increases morbidity and
mortality 45,46. Cancer cachexia is mulitfactoral and causes an energy imbalance with a
progressive loss of lean and adipose tissue attributed to decreased dietary intake as a
result of a variety of metabolic alteration including anorexia, dysphagia, dysgeusia, pain
or fatigue 47,48. Cancer combined with the chemotherapeutic regimen compromises
physical and mental status, including eating behavior. Limiting food intake partially
alleviates the discomforts caused by cancer, but in doing so exacerbates the weight loss
increasing morbidity and increasing mortality 49. Our study clearly indicated a decline in
food consumption and weight gain post DOXO administration.
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Chemotherapy induced diarrhea (CID) further contributes to the weight loss. A
serious potentially life-threatening side effect, CID is one of the most evident pathologies
associated with CIM 50-52. Various analyses suggest the pathophysiology of CID is caused
by the initial cytotoxic insult to the crypt cells of the intestinal epithelium. Diminished
digestive ability has been attributed to decreased enzyme secretory capacity, enzyme
imbalances, and altered osmotic gradients that collectively enhance the progression of
nutrition malabsorption and fluid and electrolyte losses 53.
Circulating Cytokines
The lack of changes in the measured cytokines conflicts with reports for a
decrease in the anti-inflammatory cytokine, IL-10, and increases in pro-inflammatory
cytokines, IL-6 and TNF-α, after patients receive chemotherapy 23,41,54-57. However, this
study necropsied pigs 5-6 days after administration of chemotherapy. This is earlier than
when inflammatory cytokines are reported to increase in human subjects receiving
chemotherapy. Based on conversations with our oncology colleagues at St Jude
Children’s Research Hospital, providing parenteral nutrition after the pigs cease to eat
and thereby extending the post administration period and increasing the severity of
mucositis would likely elicit the previously reported changes in circulating cytokines.
Additionally, previous reports indicate cytokines increase in response to stress factors 5861

. For the present study, several uncontrollable variables, including transport to the

animal facilities, solitary housing, dietary change, and surgical placement of the catheter
could have caused an elevation in the cytokine baseline. If so, this could have obscured
post-administration responses and differences between the control and treatment groups.
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Gross Anatomy and Histopathology
Observations at necropsy revealed lesions in the mouth and throughout the
gastrointestinal tract of pigs treated with DOXO, but not control pigs. Histological
microscopic observations coincided with findings reported by other researchers 62,63. Our
findings included observations of severe morphological and architectural damage.
Specifically, severe villus atrophy, crypt loss, disturbance of crypt arrangement,
flattening of crypt and villus epithelium, and mucosa and submucosa thickening.
Collectively, these findings confirm the diagnosis of mucositis.
Pig Versus Rodent Model
Oncology research currently has various investigational models for examining
oral and gastrointestinal mucositis, ranging from in vitro systems to rodents 37,62,64-66.
Discrepancies about interspecies comparisons emerge from the literature based on the
functional differentiation of the GIT that begins during embryological development. It
has been argued that dissimilarities of the GIT will not impact the specific mechanisms of
gastrointestinal mucositis 67. Within the same debate, the evidence provided to confirm
the similar mechanisms of chemotherapy-induced mucositis is limited. Future animal
model development requires examination of two areas. One is the relevance of the
animal, and the second is the responses of the entire gastrointestinal tract (GIT) to
eradicate gaps in information and either confirm or deny prior mucositis theories. The
porcine model developed herein shares more similarities with humans than most other
non-primate species with regard to the anatomical, physiological, immunological, and
metabolic environment of the GIT 7-9. A recent review stated, “Few consistent animal
models exist that investigate mucositis in the remainder of the gastrointestinal tract
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(GIT) 37.” These statements confirm the necessity for the development of a novel porcine
model for chemotherapy-induced mucositis.
Conclusion
This study developed a porcine model for chemotherapy-induced mucositis.
Administration of DOXO at a clinically relevant dose of 75mg/m2 induces mucositis
within 4 to 5 days post-administration. Severe morphological damage to the alimentary
tract mucosa is accompanied by declines in food consumption and weight gain, increased
frequency of vomiting, diarrhea, and lethargic behavior. Previous discussion leads to the
conclusion the weaned pig is a relevant model in which the entire GIT can be examined.
At the forefront of cancer research is the necessity for interventions that alleviate or
eliminate CIM. A better understanding of the mechanisms of mucositis will facilitate this
effort. Various agents are available for rescue post-chemotherapy administration. What if
there was a mucositis intervention available for administration with chemotherapy in
order to prevent this adverse side effect? Together with the collaboration of a team of
oncological experts, the porcine model has the potential for testing interventions to
eliminate the dose-limiting factor of CIM. Of particular interest is colostrum. The GIT is
well known to provide barrier protection and immunity. Chemotherapy introduces a
breach in this protective function. Colostrum is well known to have immunological
properties and may have great applications for patients receiving chemotherapy that
induces mucositis. Future directions for this project include a preliminary study that
evaluated colostrum as a potential intervention. This effort is currently in progress.
Colostrum has the potential to reduce the severity of mucositis, but the bioactive fractions
and mechanisms of action are unknown.
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